Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction
- VernacularTitle:维立西呱治疗射血分数降低的心力衰竭的药物经济学研究
- Author:
Feng LI
1
;
Mei HE
1
;
Lifeng MU
1
;
Ming YANG
1
Author Information
1. Dept. of Pharmacy，the Affiliated Hospital of North Medical College，Sichuan Nanchong 637000，China
- Publication Type:Journal Article
- Keywords:
vericiguat;
heart failure;
reduced ejection fraction;
cost-utility analysis;
Markov model;
Pharmacoeconomics
- From:
China Pharmacy
2023;34(15):1869-1873
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-effectiveness of vericiguat combined with standard treatment in the treatment of heart failure with reduced ejection fraction （HFrEF）. METHODS Based on the results of the VICTORIA trial and related literature， a three-state （including stable state of heart failure， hospitalized state of heart failure and death state） Markov model was constructed. The cycle length was 1 month， the time horizon was 20 years， the discount rate was 5%， and one time China’s per capita gross domestic product （GDP） in 2021 was the willing-to-pay （WTP） threshold. Cost-utility analysis was performed to evaluate the cost-effectiveness of vericiguat combined with standard treatment in the treatment of HFrEF. The output indicators included quality-adjusted life year （QALY） and incremental cost-effectiveness ratio （ICER）. The robustness of the results of the basic analysis was verified by one-way sensitivity analysis and probability sensitivity analysis. RESULTS The ICER of vericiguat combined with the standard treatment plan compared to the standard treatment plan alone was 444 341.95 yuan/QALY， which was more than WTP of this study （80 976 yuan/QALY）. One-way sensitivity analyses showed that the probability of cardiovascular death in both groups was the main influencing parameter for the robustness of the model， but they had little influence on the results of the basic analysis. The probabilistic sensitivity analysis displayed that under the WTP threshold of this study， the possibility of vericiguat combined with the standard treatment plan being more cost-effective was 2.6%. CONCLUSIONS Compared with the standard treatment plan， vericiguat combined with the standard treatment plan is not cost-effective in patients with HFrEF.
